The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Open accessAbstract
Purpose: Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors. Patients and Methods: Patients enrolled to intermittent dosing cohorts received navitoclax on day −3, followed by dosing on days 1 to 14 of a 21-day cycle. Patients on continuous dosing received a 1-week lead-in dose of 150 mg followed by continuous daily administration. Blood samples were collected for pharmacokinetic analyses, biomarker analyses, and platelet monitoring. Results: Forty-seven patients, including 29 with small-cell lung cancer (SCLC) or pulmonary carcinoid, were enrolled between 2007 and 2008, 35 on intermittent and 12 on continuous dosing cohorts. Primary toxicities included diarrhea (40%), nausea (34%), vomiting (36%), and fatigue (34%); most were grade 1 or 2. Dose- and schedule-dependent thrombocytopenia was seen in all patients. One patient with SCLC had a confirmed partial response lasting longer than 2 years, and eight patients with SCLC or carcinoid had stable disease (one remained on study for 13 months). Pro-gastrin releasing peptide (pro-GRP) was identified as a surrogate marker of Bcl-2 amplification and changes correlated with changes in tumor volume. Conclusion: Navitoclax is safe and well tolerated, with dose-dependent thrombocytopenia as the major adverse effect. Preliminary efficacy data are encouraging in SCLC. Efficacy in SCLC and the utility of pro-GRP as a marker of treatment response will be further evaluated in phase II studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“clinical trial data suggest that the dose-limiting toxicities of obatoclax may preclude sufficient target inhibition, in contrast to ABT-263 (30, 34, 35).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Bcl-xl inhibition with ABT263 and other small molecular inhibitors induces platelet apoptosis and results in severe thrombocytopenia, which prevents the use of ABT263 and other Bcl-xl specific inhibitors in the clinic—even for cancer patients—because platelets solely depend on Bcl-xl for survival24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Because both SCs and platelets, but not NCs, are primarily dependent on Bcl-xl for survival16–18,24–27 (Supplementary Fig. 1h), we evaluated the effects of PZ compared with ABT263 on the viability of WI38 NCs (Fig. 1g, left panel), IR-SCs (Fig. 1g, middle panel), and platelets (Fig. 1g, right panel).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“As reported, ABT263 was highly toxic to both WI38 IR-SCs (Fig. 1g, middle panel) and platelets16–18,24–27 (Fig. 1g, right panel; Supplementary Fig. 2).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Therefore, PZ can selectively induce apoptosis in SCs, but not platelets, which are dependent on Bcl-xl for survival while having minimal toxicity to NCs that are less sensitive to Bcl-xl inhibition than SCs16–18,24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.a115.109006 · Cited by 153
RetractedPardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109006200 · Cited by 145
RetractedAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“This is a mechanism-based toxicity induced by inhibition of Bcl-xL in circulating platelets,(13,18) which is required for platelet survival.(19,20) Here we describe a phase I dose-escalation study to evaluate the safety (with particular attention to platelet dynamics), pharmacokinetics, and preliminary efficacy of nav…”
BackgroundThe role of Bcl-2 family members in tumorigenesis
Kirkin, V., Joos, S., & Zörnig, M. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.009 · Cited by 567
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., ZAHURAK, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 475
Bcl-2 family proteins are essential for platelet survival
Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Ben-Ezra JM, 1994, Am J Pathol, 145, 1036
- Brambilla E, 1996, Am J Pathol, 149, 1941
Cited by
Sorted by citations
Items 301–400 of 616
Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer
de Paula, B., Kieran, R., Koh, S. S. Y., Crocamo, S., Abdelhay, E. S. F. W., & Muñoz‐Espín, D. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0643 · Cited by 32
Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells
Stamelos, V. A., Robinson, E., Redman, C. W. E., & Richardson, A. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.019 · Cited by 30
Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
Okumura, S., & Janne, P. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2365 · Cited by 30
Broecker‐Preuss, M., Becher-Boveleth, N., Müller, S. P., & Mann, K. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0303-8 · Cited by 30
8-Chrysoeriol, as a potential BCL-2 inhibitor triggers apoptosis of SW1990 pancreatic cancer cells
Zhang, Y., Li, Z., Min, Q., Palida, A., Zhang, Y., Tang, R., Chen, L., & Li, H. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.01.042 · Cited by 30
Vivo‐Llorca, G., Candela‐Noguera, V., Alfonso, M., García‐Fernández, A., Orzáez, M., Sancenón, F., & Martínez‐Máñez, R. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202001579 · Cited by 29
Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
Shebl, B., Ng, D., Lalazar, G., Rosemore, C., Finkelstein, T. M., Migler, R. D., Zheng, G., Zhang, P., Jiang, C. S., Qureshi, A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161820 · Cited by 29
Kalenkiewicz, A., Grant, B. J., & Yang, C. (2015) · Biology · doi:10.3390/biology4020344 · Cited by 29
BCL-2 Inhibitors Sensitize Therapy-resistant Chronic Lymphocytic Leukemia Cells to VSV Oncolysis
Samuel, S., Beljanski, V., van Grevenynghe, J., Richards, S. M., Yebdri, F. B., He, Z., Nichols, C. N., Belgnaoui, S. M., Steel, C., Goulet, M.-L., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.91 · Cited by 29
Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers
Modugno, M., Banfi, P., Gasparri, F., Borzilleri, R. M., Carter, P., Cornelius, L. A. M., Gottardis, M. M., Lee, V., Mapelli, C., Naglich, J. G., et al. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.11.022 · Cited by 29
Cinar, M., ROSENFELT, F. P., Rokhsar, S., Lopategui, J. R., Pillai, R. K., Cervania, M., Pao, A., Cinar, B., & Alkan, S. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.04.003 · Cited by 29
Identification of small molecule inhibitors of Interleukin-18
Krumm, B., Meng, X., Xiang, Y., & Deng, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-00532-x · Cited by 29
Judd, A. S., Bawa, B., Buck, W. R., Tao, Z., Li, Y., Mitten, M. J., Bruncko, M., Catron, N. D., Doherty, G. A., Durbin, K. R., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado7120 · Cited by 28
Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL
Hari, Y., Harashima, N., Tajima, Y., & Harada, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5881 · Cited by 28
ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
Yang, X., Xiao, Y., Zhong, C., Shu, F., Xiao, S., Zheng, Y., & Xia, Z. (2020) · Frontiers in Pharmacology · doi:10.2139/ssrn.3698857 · Cited by 28
Ionic liquid-mediated delivery of a BCL-2 inhibitor for topical treatment of skin melanoma
Huda, M. N., Deaguero, I. G., Borrego, E. A., Kumar, R., Islam, T., Afrin, H., Varela-Ramı́rez, A., Aguilera, R. J., Tanner, E. E. L., & Nurunnabi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.035 · Cited by 28
Lakhani, N. J., Rasco, D. W., Wang, H., Men, L., Liang, E., Fu, T., Collins, M. C., Min, P., Yin, Y., Davids, M. S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1525 · Cited by 28
Zou, M., Xia, S., Zhuang, L., Han, N., Chu, Q., Chao, T., Peng, P., Chen, Y., Gui, Q., & Yu, S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1895 · Cited by 28
How Many Diseases Are Colorectal Cancer?
Greystoke, A., & Mullamitha, S. (2012) · Gastroenterology Research and Practice · doi:10.1155/2012/564741 · Cited by 28
Brock, K., Homer, V., Soul, G., Potter, C., Chiuzan, C. C., & Lee, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08440-0 · Cited by 29
Ahmad, A., Braden, A. A., Khan, S., Xiao, J., & Khan, M. M. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01016-7 · Cited by 31
Chen, Y., Huang, C., Shi, Y., Lee, Y., Wang, L., & Chang, L. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.09.008 · Cited by 27
Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers
Fairlie, W. D., & Lee, E. F. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210750 · Cited by 28
Singh, A., Jayanthan, A., Farran, A., Elwi, A. N., Kim, S.-W., Farran, P. R., & Narendran, A. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.06.035 · Cited by 27
Dose-finding designs for trials of molecularly targeted agents and immunotherapies
Chiuzan, C. C., Shtaynberger, J., Manji, G. A., Duong, J., Schwartz, G. K., Ivanova, A., & Lee, S. M. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1289952 · Cited by 28
Mcl-1 regulates reactive oxygen species via NOX4 during chemotherapy-induced senescence
Demelash, A., Pfannenstiel, L. W., Liu, L., & Gastman, B. (2017) · Oncotarget · doi:10.18632/oncotarget.15962 · Cited by 27
Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review
Saxena, R., Welsh, C. M., & He, Y.-W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1462339 · Cited by 29
The development of targeted therapy in small cell lung cancer.
Zhang, Y., & He, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.07.04 · Cited by 26
Personalized Therapy of Small Cell Lung Cancer
Schneider, B. J., & Kalemkerian, G. P. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_9 · Cited by 26
The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer
Matos, B., Howl, J., Jerónimo, C., & Fardilha, M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105145 · Cited by 26
Smedley, C. J., Zheng, Q., Gao, B., Li, S., Molino, A., Duivenvoorden, H. M., Parker, B. S., Wilson, D. J. D., Sharpless, K. B., & Moses, J. E. (2019) · Angewandte Chemie · doi:10.1002/ange.201813761 · Cited by 26
Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B
van de Kooij, B., Rooswinkel, R. W., Kok, F. K., Herrebout, M. A. C., de Vries, E., Paauwe, M., Janssen, G. M. C., van Veelen, P. A., & Borst, J. G. (2013) · Oncogene · doi:10.1038/onc.2013.99 · Cited by 26
Li, G., Zhang, S., Fang, H., Yan, B., Zhao, Y., Feng, L., Ma, X.-X., & Ye, X. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.018 · Cited by 26
Finnegan, R., Elshazly, A. M., Patel, N. H., Tyutyunyk‐Massey, L., Tran, T. H., Kumarasamy, V. M., Knudsen, E. S., & Gewirtz, D. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.966441 · Cited by 25
Cummings, J., Zweifel, M., Smith, N., Ross, P., Peters, J., Rustin, G. J. S., Price, P., Middleton, M. R., Ward, T. H., & Dive, C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.165 · Cited by 25
Self-citationZheng, C., Yang, H., Zhang, M., Lu, S., Shi, D., Wang, J., Chen, X., Ren, X., Liu, J., Lv, J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.101 · Cited by 25
Lee, J., Park, K., Alberobello, A. T., Kallakury, B., Weng, M., Wang, Y., & Giaccone, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1110 · Cited by 25
Στρατικόπουλος, Η., Kiess, N., Szabolcs, M. J., Pegno, S., Cheung, K., Wu, X., Poulikakos, P. I., Cheung, P., Schmidt, H., & Parsons, R. E. (2018) · Oncogene · doi:10.1038/s41388-018-0436-4 · Cited by 25
Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies
Mukherjee, N., Sheetz, J., & Shellman, Y. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209859 · Cited by 24
The Regulation of Platelet Life Span
Josefsson, E. C., Dowling, M. R., Lebois, M., & Kile, B. T. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387837-3.00003-1 · Cited by 24
Jackson, M. R., Ashton, M., Koessinger, A. L., Dick, C., Verheij, M., & Chalmers, A. J. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.11.029 · Cited by 24
Targeting the apoptosis pathway to treat tumours of the paediatric nervous system
Fitzgerald, M.-C., O’Halloran, P. J., Connolly, N. M. C., & Murphy, B. M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04900-y · Cited by 26
Kang, K., Chuai, J.-B., Xie, B.-D., Li, J., Qu, H., Wu, H. K., Fang, S., Cui, J., Xiu, L.-L., Han, J., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119574 · Cited by 24
Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer
Lin, Y., Lai, Q., Gou, L., Feng, J., & Yang, J. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1797050 · Cited by 25
Chaudhari, S. B., Kumar, A., Mankar, V. H., Banerjee, S., Kumar, D., Mubarak, N. M., & Dehghani, M. H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32434 · Cited by 23
Desrat, S., Remeur, C., & Roussi, F. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00354g · Cited by 23
Mehrotra, N., Anees, M., Tiwari, S., Kharbanda, S. M., & Singh, H. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102627 · Cited by 23
Fournier, F., Diaz-Marin, R., Pilon, F., Neault, M., Juneau, R., Girouard, G., Wilson, A. M., Larrivée, B., Mallette, F. A., Crespo‐Garcia, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209973120 · Cited by 23
Miebach, L., Melo‐Zainzinger, G., Freund, E., Clemen, R., Cecchini, A. L., & Bekeschus, S. (2023) · Advanced Science · doi:10.1002/advs.202303183 · Cited by 24
Liu, Y., Zhang, Z., Song, T., Liang, F., Xie, M., & Sheng, H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12243 · Cited by 23
Stamelos, V. A., Redman, C. W. E., & Richardson, A. (2012) · Journal of Molecular Signaling · doi:10.1186/1750-2187-7-12 · Cited by 23
Kasai, S., Sasaki, T., Watanabe, A., Nishiya, M., Yasuhira, S., Shibazaki, M., & Maesawa, C. (2017) · Oncology Letters · doi:10.3892/ol.2017.6211 · Cited by 23
The context-dependent effect of cellular senescence: From embryogenesis and wound healing to aging
Lavarti, R., Alvarez-Diaz, T., Marti, K., Kar, P., & Raju, R. P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102760 · Cited by 21
YES1 Is a Druggable Oncogenic Target in SCLC
Redín, E., Garrido-Martin, E. M., Valencia, K., Redrado, M., Solórzano, J. L., Carias, R., Echepare, M., Expósito, F., Serrano, D., Ferrer, I., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.08.002 · Cited by 22
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer
Sarosiek, K. A., & Wood, K. C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.004 · Cited by 23
Kong, S. M., Moharil, P., Handly‐Santana, A., Boehnke, N., Panayiotou, R., Gomerdinger, V. F., Covarrubias, G., Pires, I. S., Zervantonakis, I. K., Brugge, J. S., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10429 · Cited by 22
Xu, X., Dai, F., Mao, Y., Zhang, K., Qin, Y., & Zheng, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1242488 · Cited by 22
Mathieu, A., Spérandio, O., Pottiez, V., Balzarin, S., Herlédan, A., Elkaïm, J., Fogeron, M., Piveteau, C., Dassonneville, S., Deprez, B. P., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114534070 · Cited by 22
Muttiah, C., Whittle, J. R., Oakman, C. A., & Lindeman, G. J. (2022) · Future Oncology · doi:10.2217/fon-2021-1450 · Cited by 21
Jaiswal, A., Jaiswal, A. S., Williamson, E. A., Gelfond, J. A. L., Zheng, G., Zhou, D., & Hromas, R. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04490-8 · Cited by 22
Yang, D., He, L., Ma, S.-Q., Li, S., Zhang, Y., Hu, C., Huang, J., Xu, Z., Tang, D., & Chen, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076662 · Cited by 21
Ke, J.-Y., Zhang, W., Gong, R., Cen, W., Huang, H.-Q., Li, Y.-R., Kong, W.-D., & Jiang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-5376-4 · Cited by 21
Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
Marczyk, M., Patwardhan, G. A., Zhao, J., Qu, R., Li, X., Wali, V. B., Gupta, A. K., Pillai, M. M., Kluger, Y., Yan, Q., et al. (2020) · Cancers · doi:10.3390/cancers12092551 · Cited by 21
Ji, X., Dong, X., Li, J., Tai, G., Qiu, S., Wei, W., Silumbwe, C. W., Damdinjav, D., Otieno, J. N., Li, X., et al. (2025) · Phytotherapy Research · doi:10.1002/ptr.8507 · Cited by 23
Gorombei, P., Guidez, F., Ganesan, S., Chiquet, M., Pellagatti, A., Goursaud, L., Tekin, N., Beurlet, S., Patel, S., Guerenne, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910658 · Cited by 20
Advances in Nanotherapy for Targeting Senescent Cells
Shi, Y., Zhang, Y., Zhang, Y., Yao, J., Guo, J., Xu, X., & Wang, L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s469110 · Cited by 20
Arulananda, S., Lee, E. F., Fairlie, W. D., & John, T. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1856660 · Cited by 19
Drug Resistance and Molecular Cancer Therapy: Apoptosis Versus Autophagy
Trowman, R., Bryan, W., Nicholas, F., & Xu, L. (2013) · InTech eBooks · doi:10.5772/55415 · Cited by 20
Jana, T., Ghosh, A., Mandal, S. D., Banerjee, R., & Saha, S. (2017) · Royal Society Open Science · doi:10.1098/rsos.160501 · Cited by 19
Liu, J., Zhou, F., Zhang, L., Wang, H., Zhang, J., Zhang, C., Jiang, Z., Li, Y., Liu, Z., & Chen, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.074 · Cited by 19
Duan, Z., Chinn, D. C., Tu, M., Zhang, Q.-Y., Huynh, J., Chen, J. B., Mack, P. C., Yu, A., & Kim, E. J.-H. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.01.009 · Cited by 19
Lee, J., Kim, J. O., Jung, C. K., Kim, Y. S., Yoo, I. R., Choi, W. H., Jeon, E. K., Hong, S. H., Chun, S. H., Kim, S. J., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.09.005 · Cited by 19
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
de Graaff, M. A., de Rooij, M. A. J., van den Akker, B. E. W. M., Gelderblom, H. A. J., Chibon, F., Coindre, J., Mariño‐Enríquez, A., Fletcher, J. A., Cleton-Jansen, A., & Bovée, J. V. M. G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.117 · Cited by 19
Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer
Lee, E. F., & Fairlie, W. D. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210749 · Cited by 18
Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors
Almehdi, A. M., Soliman, S. S. M., El‐Shorbagi, A., Westwell, A. D., & Hamdy, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914656 · Cited by 18
Clinical advances in TNC delivery vectors and their conjugate agents
Chen, W., Wu, Y., Wang, J., Yu, W., Shen, X., Zhao, K., Liang, B., Hu, X., Wang, S., Jiang, H., et al. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108577 · Cited by 18
Systemic therapy for pulmonary carcinoids
Márquez-Medina, D., & Popat, S. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.018 · Cited by 18
Biomarkers of cell death applicable to early clinical trials
Dean, E. J., Greystoke, A., Ranson, M., & Dive, C. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.03.020 · Cited by 18
Self-citationYeast “N”-hybrid systems for protein–protein and drug–protein interaction discovery
Rezwan, M., & Auerbach, D. (2012) · Methods · doi:10.1016/j.ymeth.2012.06.006 · Cited by 20
Xu, H., Sun, Y., Huang, C., You, B., Ye, D., & Chang, C. (2020) · Cancers · doi:10.3390/cancers12040831 · Cited by 18
Water-soluble inhibitors of ABCG2 (BCRP) – A fragment-based and computational approach
Antoni, F., Wifling, D., & Bernhardt, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112958 · Cited by 18
Chemogenomics for drug discovery: clinical molecules from open access chemical probes
Quinlan, R. B. A., & Brennan, P. E. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00016k · Cited by 18
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins
Pal, P., Zhang, P., Poddar, S. K., & Zheng, G. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2116311 · Cited by 18
Towards the next generation of dual Bcl-2/Bcl-xL inhibitors
Varnes, J. G., Gero, T. W., Huang, S., Diebold, R. B., Ogoe, C. A., Grover, P. T., Su, M., Mukherjee, P. K., Saeh, J. C., Macintyre, T., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.036 · Cited by 18
Olsen, R. R., Mary-Sinclair, M. N., Yin, Z., & Freeman, K. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116998 · Cited by 17
Hardouin, C., Baillard, S., Barière, F., Copin, C., Craquelin, A., Janvier, S., Lemaitre, S., Roux, S. L., Russo, O., & Samson, S. (2019) · Organic Process Research & Development · doi:10.1021/acs.oprd.9b00364 · Cited by 17
Oh, Y., Jung, H. R., Min, S., Kang, J., Jang, D., Shin, S., Kim, J., Lee, S. E., Sung, C. O., Lee, W., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.018 · Cited by 17
Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode
Hedir, S., Giorgi, M. D., Fogha, J., Pascale, M. D., Weiswald, L., Brotin, É., Marekha, B., Denoyelle, C., Denis, C., Suzanne, P., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.003 · Cited by 20
Shimada, K., Tomita, A., Minami, Y., Abe, A., Hind, C. K., Kiyoi, H., Cragg, M. S., & Naoe, T. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.05.007 · Cited by 17
Novel Therapeutic Options for Small Cell Lung Cancer
Canova, S., Trevisan, B., Abbate, M. I., Colonese, F., Sala, L., Baggi, A., Bianchi, S. P., D'Agostino, A. G., & Cortinovis, D. L. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01465-7 · Cited by 16
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Kawakatsu, R., Tadagaki, K., Yamasaki, K., & Yoshida, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-55286-0 · Cited by 16
Thorman, A. W., Reigle, J. K., Chutipongtanate, S., Yang, J., Shamsaei, B., Pilarczyk, M., Fazel‐Najafabadi, M., Adamczak, R., Kouril, M., Bhatnagar, S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj3010 · Cited by 16
Computational study and peptide inhibitors design for the CDK9 – cyclin T1 complex
Randjelović, J., Erić, S., & Savić, V. (2013) · Journal of Molecular Modeling · doi:10.1007/s00894-012-1735-2 · Cited by 16
Emerging Biomarkers in Personalized Therapy of Lung Cancer
Cagle, P. T., Raparia, K., & Portier, B. P. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_2 · Cited by 16
Wieczorek, S., Breitenbuecher, F., Soni, A., Paul‐Konietzko, K., Ziegler, S., Sak, A., Iliakis, G. E., & Schüler, M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2427-1 · Cited by 16
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
Bose, P., Masárová, L., & Verstovšek, S. (2020) · Cancers · doi:10.3390/cancers12102891 · Cited by 16
Lee, J. M., Kim, H.-S., Kim, A., Chang, Y. S., Lee, J. G., Cho, J., & Kim, E. Y. (2021) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.1.16 · Cited by 16
Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomasPreprint
Norton, J. P., Augert, A., Eastwood, E., Basom, R., Rudin, C. M., & MacPherson, D. P. (2021) · Genes & Development · doi:10.1101/gad.348316.121 · Cited by 16
Self-citationTargeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound
Liu, J., Tian, Z., Zhou, N., Liu, X., Liao, C., Lei, B., Li, J., Zhang, S., & Chen, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17294 · Cited by 15
Cell-penetrating Alphabody protein scaffolds for intracellular drug targeting
Pannecoucke, E., Trimpont, M. V., Desmet, J., Pieters, T., Reunes, L., Demoen, L., Vuylsteke, M., Loverix, S., Vandenbroucke, K., Alard, P., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1682 · Cited by 15
Metadata
- Authors
- Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., Dive, C., Enschede, S. H., Nolan, C., Chiu, Y.-L., Busman, T., Xiong, H., Krivoshik, A. P., Humerickhouse, R., Shapiro, G. I., & Rudin, C. M.
- Affiliations
- Rush University Medical Center (US)
- From the Dana-Farber Cancer Institute, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Northwest Medical Specialties, Tacoma, WA; Rush University Medical Center, Chicago; Abbott Laboratories, Abbott Park, IL; University of California Davis Cancer Center, Sacramento, CA; Sunterra Oncology Associates, Phoenix, AZ; Johns Hopkins University, Baltimore, MD; and Paterson Institute for Cancer Research, University of Manchester, United Kingdom.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-01
- Volume
- 29
- Issue
- 7
- Pages
- 909-916
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC4668282
- OpenAlex
- W2119316461
- Cited by
- 603
- References
- 39
- Citations by year
- 2026: 35 · 2025: 28 · 2024: 30 · 2023: 34 · 2022: 32 · 2021: 37 · 2020: 39 · 2019: 29 · 2018: 33 · 2017: 31 · 2016: 40 · 2015: 46 · 2014: 57 · 2013: 54 · 2012: 51
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- navitoclax, BCL-2 inhibitor, small cell lung cancer, bronchial carcinoid, thrombocytopenia, progastrin-releasing peptide, apoptosis resistance, pharmacokinetics, safety and tolerability, intermittent dosing, continuous dosing, surrogate markers
- MeSH terms
- Administration, Oral, Aged, Aged, 80 and over, Aniline Compounds, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasms, Prognosis, Sulfonamides, Survival Analysis, Treatment Outcome, Risk Assessment, Genes, bcl-2, Maximum Tolerated Dose, Small Cell Lung Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
